Search Results for "INFeD"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for INFeD. Results 1 to 2 of 2 total matches.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
INF beta-1a 30 mcg 0.35 2.84 0.43
once/week
RADIANCE (n=1313)4
Ozanimod 0.46 mg 0.22* 2.09* 0.20 ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
Alemtuzumab – Lemtrada ~55% (vs INF)6 12 mg IV once/day x 5 days Infusion reactions, nasopharyngitis ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.